QUÉBEC CITY, May 8, 2013
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") announces the results of the vote on directors
held earlier today at its annual meeting of shareholders. Issuers
listed on the Toronto Stock Exchange are required to issue a news
release providing this information.
Each of the director nominees proposed by management for
election was elected as director, without a vote by ballot being
conducted. The Company received proxies with regard to voting on
the seven directors nominated for election as set forth in the
table below:
Name of Nominee |
Votes For |
% |
Votes Withheld |
% |
Marcel Aubut |
2,379,194 |
70.8 |
979,320 |
29.2 |
David A. Dodd* |
2,385,312 |
71.0 |
973,202 |
29.0 |
José P. Dorais |
2,692,560 |
80.2 |
665,954 |
19.8 |
Carolyn Egbert |
2,351,610 |
70.0 |
1,006,903 |
30.0 |
Juergen Ernst |
2,339,417 |
69.7 |
1,019,097 |
30.3 |
Pierre Lapalme |
2,375,050 |
70.7 |
982,964 |
29.3 |
Gérald Limoges |
2,380,610 |
70.9 |
977,404 |
29.1 |
(*) |
The results for the proxies received regarding Mr. Dodd were
originally received for the Company's former President and Chief
Executive Officer and director, Prof. Juergen Engel. As announced
by the Company on April 15, 2013, Mr. Dodd succeeded to Prof. Engel
as President and Chief Executive Officer, and Mr. Dodd was also
concurrently appointed to the Board of Directors. At the same time,
the Company announced that Mr. Dodd would be one of the
management director nominees for election at the Company's
annual meeting of shareholders and that Management
proxy holders intended to exercise the discretion granted in the
proxies to vote in favour of the election of Mr. Dodd as a director
at the shareholders' meeting. |
All other matters at the shareholders' meeting, namely the
renewal of and amendment to the Company's Stock Option Plan, the
reconfirmation and approval of the Shareholder Rights Plan and the
confirmation of an amendment to the Company's bylaws, were also
approved by shareholders.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For more information please visit
www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.